Abstract
Abstract Background:Arsenic compound has shown excellent activity in APL. Its anticancer activity in solid tumors is still being explored. We have tested realgar, arsenic sulfide (As4A4), in gastric cancer cells to understand its anticancer activity and mechanism. Methods: The effects of the realgar on cell proliferation and apoptosis of AGS and MGC803 cell lines were determined using methyl thiazolyl tetrazolium (MTT) assay and Annexin V assay. Western blot analysis was used to detect the related pathways by measuring the expression levels of apoptotic proteins such as Bax, Bcl-2, c-myc, p53 and mdm2. Real-time PCR analysis was used to measure the mRNA levels of the related genes. Results: Realgar significantly inhibited proliferation and induced apoptosis in gastric cancer cell lines AGS and MGC803 in a dose- and time-dependent manner, particularly in AGS cells. Realgar up-regulated the expression of p53 and p53 target genes MDM2 and Bax, down-regulated the expression of Bcl-2 and c-Myc in AGS cell lines, indicating that realgar could induce apoptosis via p53-bax pathway in AGS cell lines. However, similar dose of realgar up-regulated the expression of Bax, down-regulated the expression of Bcl-2 and c-Myc in MGC803 cell lines, with much less effect on the expression of p53. Conclusion: Realgar has significant anti-cancer effect on gastric cancer cell lines through inhibiting cell proliferation and inducing apoptosis. Our findings suggest a potential therapeutic effect of realgar in gastric cancer and further study in this area is needed. Citation Format: Siyu Chen, Wei Tian, Wenping Ding, Leizhen Zheng, Xiaoping Li, Li Zhang, Jianchun Gu, shuangfen Tao, Sungkyoung Kim, Wenhua Gu. Realgar exerts cytotoxic killing of gastric cancer cells through Bax apoptotic pathway. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2110. doi:10.1158/1538-7445.AM2013-2110
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
